Wedbush Reiterates Outperform on Aerovate Therapeutics, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Aerovate Therapeutics (NASDAQ:AVTE) and maintained a price target of $41.
May 22, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Aerovate Therapeutics and maintained a price target of $41.
The reiteration of an Outperform rating and the maintenance of a $41 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100